US 11,851,501 B2
Multispecific antibodies
Germaine Fuh, Pacifica, CA (US); and Jenny M. Bostrom, South San Francisco, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Apr. 16, 2021, as Appl. No. 17/232,537.
Application 17/232,537 is a division of application No. 16/133,536, filed on Sep. 17, 2018, granted, now 11,008,401.
Application 16/133,536 is a division of application No. 11/893,693, filed on Aug. 17, 2007, granted, now 10,118,970, issued on Nov. 6, 2018.
Claims priority of provisional application 60/937,814, filed on Jun. 28, 2007.
Claims priority of provisional application 60/841,350, filed on Aug. 30, 2006.
Prior Publication US 2022/0033515 A1, Feb. 3, 2022
Int. Cl. C07K 16/32 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); C07K 16/42 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/32 (2013.01) [C07K 16/22 (2013.01); C07K 16/2878 (2013.01); C07K 16/4283 (2013.01); C07K 16/468 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01)] 15 Claims
 
1. A multispecific antibody capable of binding to a first epitope on VEGF and a second epitope on HER2, wherein the multispecific antibody comprises an antigen-binding site comprising a light chain variable domain (VL) comprising the following complementarity determining regions (CDRs):
(a) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 24,
(b) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 25, and
(c) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 26, and
a heavy chain variable domain (VH) comprising the following CDRs:
(d) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1,
(e) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 2, and
(f) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 3, and
wherein the antigen-binding site is capable of binding to the first epitope and the second epitope.